Navigation Links
Schering-Plough Announces Transition of Animal Health Leadership
Date:10/17/2008

KENILWORTH, N.J., Oct. 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced the transition of leadership of its Animal Health unit from Ruurd Stolp, D.V.M., Ph.D., to Raul E. Kohan, who was previously the Deputy Head of the Animal Health unit. In his role as senior vice president and president, Intervet/Schering-Plough Animal Health, Kohan will continue reporting to Fred Hassan, chairman and chief executive officer.

In this role, Kohan is responsible for overseeing the company's worldwide animal health business, which includes a range of pharmaceuticals, vaccines and services for food-producing and companion animals. The role is based in Boxmeer, the Netherlands, where the Animal Health unit is headquartered.

Kohan joined Schering-Plough in 1984 and has since held positions of increasing responsibility. He recently served as Deputy Head of Animal Health and senior vice president, Corporate Excellence and Administrative Services for Schering-Plough Corporation. Previously, Kohan's responsibilities included overseeing the company's Global Specialty Operations group, which comprised Animal Health and Consumer Health Care for Schering-Plough.

Kohan graduated from the General San Martin Military Academy, Argentina, and holds an M.B.A. degree in economics from the University of Buenos Aires.

Stolp will transition responsibilities to Kohan over the next several months. During his 21 years with Intervet, Stolp held various roles of increasing responsibility within the Animal Health unit. Previously, Stolp was president of Intervet International, a position he held since 2002.

"Ruurd and Raul played critical leadership roles in our successful combination of Organon BioSciences with Schering-Plough over the past year," said Hassan. "I thank Ruurd for his leadership, guidance and important contributions bringing our two companies together. Raul and I look forward to working with him in an advisory capacity."

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

Media Contact

Steve Galpin, Jr.

+1 908 298 7415

Sabine Schueller

+31 485 58 7085

Investor Contacts

Janet Barth

Joseph Romanelli

+1 908 298 7436


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Schering-Plough and Merck Announce Withdrawal of Loratadine/Montelukast NDA and Termination of Respiratory Joint Venture
2. Hagens Berman Appointed Co-Lead Counsel in Case Against Schering-Plough and Merck
3. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
4. Bayer/Schering-Plough/Shionogis Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia
5. Schering-Plough Announces Expanded Stock Retention Guidelines for Senior Management
6. Schering-Plough to Webcast Presentation by CEO Fred Hassan at Lehman Brothers Eleventh Annual Global Healthcare Conference
7. Schering-Plough Promotes Ian Mcinnes to President of Global Supply Chain
8. CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough
9. Lawsuit Filed in Florida Federal Court Over Marketing of Vytorin and Zetia By Merck and Schering-Plough
10. Schering-Plough CEO to Buy $2 Million in Common Shares
11. Schering-Plough Board Elects Dr. Craig B. Thompson as a Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 2016 , ... CloudLIMS.com, a class-leading provider of Laboratory Management ... Lite helps biobanks, clinical, research and testing laboratories keep track of their biospecimens, ... is a faster and a more efficient product, allowing batch processing of data, ...
(Date:12/2/2016)... West Milford, NJ (PRWEB) , ... December 02, 2016 , ... ... Norway, Nothing Water has some unique properties including its unmatched natural purity of just ... described as clean and crisp. , Nothing Water has been available in several ShopRite ...
(Date:12/2/2016)... , ... December 02, 2016 , ... "Pro3rd Accents Volume ... editors to create versatile lower third titles with just a few clicks of the ... Volume 2 includes 30 lower third animations. Choose from various styles with accented animations, ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... pharmaceutical organizations to build intelligent, connected applications, was named the best Sales Team ... , The winner announcement was made today by the Software & Information Industry ...
(Date:11/30/2016)... ... November 30, 2016 , ... The Fertility ... designated as a Cigna Infertility Center of Excellence. The Cigna Center of Excellence ... “It’s an honor to be designated a Cigna Infertility Center of Excellence," said ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 1, 2016  Today, Simpson Healthcare Executives, ... honor of being selected as winners of multiple awards ... Executives Website at the PLATINUM level, Blue Zones Menu ... at the GOLD Level, and our proprietary 3ConneX Platform ... Simpson Healthcare Executives, we are excited to showcase our ...
(Date:12/2/2016)... BRUSSELS , Dec. 2, 2016  UCB is pleased to ... presentation at the upcoming 70 th American Epilepsy Society ... Houston, TX , USA. 1-12 ... safety and efficacy profile of VIMPAT ® (lacosamide) CV ... also share findings on the current state of the union ...
(Date:12/2/2016)... Dec. 2, 2016 Allergan plc (NYSE: ... information on its previously announced Accelerated Share Repurchase (ASR) Program. ... ... As previously announced, the Company entered into a ... the Company will repurchase $10 billion of its ordinary shares. ...
Breaking Medicine Technology: